Abstract
Surfactant replacement is an effective treatment for neonatal respiratory distress syndrome. (RDS). As widespread use of surfactant is becoming a reality, it is important to assess the economic.implications of this new form of therapy. A comparison study was carried out at the Neonatal Intensive Care Unit (NICU) of Northwest Armed Forces Hospital, Saudi Arabia. Among 75 infants who received surfactant for RDS and similar number who were managed during time period just before the surfactant was available, but by set criteria would have made them eligible for surfactant. All other management modalities except surfactant were the same for all these babies. Based on the intensity of monitoring and nursing care required by the baby, the level of care was divided as: Level IIIA, IIIB, Level II, Level I. The cost per day per bed for each level was calculated, taking into account the use of hosptital immovable equipment, personal salaries of nursing, medical, ancillary staff, overheads and maintenance, depreciation and replacement costs. Medications used, procedures done, TPN, oxygen, were all added to individual patient’s total expenditure. 75 infants in the Surfactant group had 62 survivors. They spent a total of 4300 days in hospital, (av 69.35) Out of which 970d (av 15.65 per patient) were ventilated days. There were 56 survivors in the non-surfactant group of 75. They had spent a total of 5023 days in the hospital (av 89.69/patient) out of which 1490 were ventilated days (av 26.60 d). Including the cost of surfactant (two doses), cost of hospital stay for each infant taking the average figures of stay would be SR 118,009.75 per surfactant treated baby and SR 164,070.70 per non-surfactant treated baby. The difference of 46,061 SR is 39.03% more in non-surfactant group. One Saudi rial = 8Rs (approx at the time study was carried out.) Medical care cost varies from place to place. However, it is definitely cost-effective where surfactant is concerned. Quality adjusted life years (QALY) for NICU care compares favourably with cost per QALY of several forms of adult health interventions. Audit, both medical and financial, of these services, at regular intervals is essential.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Enhorning G, Shennan A, Possamayer Fet al. Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: A randomised clinical trial.Pediatri 1985; 76:145–153.
Hallman M, Merritt TA, Javenpaa ALet al. Exogenous surfactant for treatment of severe respiratory distress syndrome: A randomised prospective clinical trial.J Pediatr 1985; 106 : 963–969.
Collaborative European Multicentre Study Group: Surfactant replacement therapy for severe neonatal respiratory distress syndrome. An international randomised clinical trial.Pediatr 1988; 82 : 683–691.
Boyle MH, Torrance GW, Sinclair JC, Horwood SP. Economic evaluation of neonatal intensive care of very low birth weight infants.NEJM 1983 ; 1330–1336.
Mugford M, Piercy J, Chalmers I. Cost implications of different approaches to the prevention of respiratory distress syndrome.Arch Dis Child 1991; 66: 757–764.
Tubman TRJ, Haliday HL, Normand C. Cost of surfactant replacement treatment for severe neonatal respiratory distress syndrome: a randomised controlled trial.BMJ 1990; 301 : 842–845.
British Paediatric Association and British Association of Perinatal Medicine. Categories of babies requiring neonatal care.Arch Dis Child 1985; 60: 599–603.
Hodges S, Fordham R, Field DJ, Norm and C, Mason E, Burton P. Cost of neonatal care in the Trent Region. (Abstr P 23). Proceedings of 61st Annual meeting of the British Pediatric Association, York 1989.
Newns B, Drummond MF, Durbin GM, Culley P. Costs and outcomes in a regional neonatal intensive care unit.Arch Dis Child 1984; 59: 1064–1069.
Scottish health service costs. Scottish Health Services Common Services Agency 1988.
Yu VYH, Bajuk B. Medical expenses of neonatal care for VLBW infants.Austr Paediatr J 1981; 17: 183–185.
Sandhu B, Stevenson RC, Cooke RWI, Pharoah POD. Cost of neonatal intensive care of very low birth weight infants.Lancet 1986; 303: 100–107.
Ryan S, Sics A, Congdon P. Cost of neonatal care.Arch Dis Child. 1988; 63: 303–308.
Connolly M, Fox G, O’Connor G, Clarke T, Mathew T. Cost of neonatal intensive and special care.Ir Med J 1989; 82: 34–39.
Phibbs CS, Wiliams RL, Phibbs RH. Newborn risk factors and costs of neonatal intensive care.Pediatr 1981; 68: 313–321.
The OSIRIS Collaborative group. Early versus delayed neonatal administration of a synthetic surfactant-the judgement of OSIRIS.Lancet 1992; 340: 1363–1369.
Vaucher YE, Harker L, Meritt TA. Outcome at twelve months of adjusted age in very lowbirth weight infants with lung immaturity: A randomised, placebo controlled trial of human surfactant.J Pediatr 1993; 122 : 126–132.
Schering SA, Piecuch RE, Leonard CH. Medical and neurodevelopmental outcome of extremely lowbirth weight infants.Pediatr Res 1993; 33: 275.
Gudex C, Kind P. The QALY toolkit. Centre for Health Economics Discussion. Paper no 38. University of York 1988.
Williams A. Economics of coronary artery bypass grafting.BMJ 1985; 291: 326–329.
Tudehope DI, Lee W, Harris F, Addison C. Cost analysis of neonatal intensive care and special care.Austr Paediatr J 1989; 25: 61–65.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pejaver, R.K., AlHifzi, I. & Aldussari, S. Surfactant replacement therapy—economic impact. Indian J Pediatr 68, 501–505 (2001). https://doi.org/10.1007/BF02723239
Issue Date:
DOI: https://doi.org/10.1007/BF02723239